Chen Lingfeng, Jin Yiyi, Fu Weitao, Xiao Siyang, Feng Chen, Fang Bo, Gu Yugui, Li Chenglong, Zhao Yunjie, Liu Zhiguo, Liang Guang
Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
School of Chemical Engineering, Nanjing University of Science and Technology, Nanjing, Jiangsu, 210094, China.
ChemMedChem. 2017 Jul 6;12(13):1022-1032. doi: 10.1002/cmdc.201700175. Epub 2017 Jun 12.
Acute lung injury (ALI) has a high lethality rate, and interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) contribute most to tissue deterioration in cases of ALI. In this study, we designed and synthesized a new series of thiazolo[3,2-a]pyrimidine derivatives based on a previously identified lead compound, and we evaluated their anti-inflammatory activities. Structure-activity relationship studies led to the discovery of two highly potent inhibitors. The two promising compounds were found to inhibit lipopolysaccharide (LPS)-induced IL-6 and TNF-α release in a dose-dependent manner in mouse primary peritoneal macrophages (MPMs). Furthermore, administration of these compounds resulted in lung histopathological improvements and attenuated LPS-induced ALI in vivo. Taken together, these data indicate that these novel thiazolo[3,2-a]pyrimidine derivatives could be developed as candidate drugs for the treatment of ALI.
急性肺损伤(ALI)致死率高,白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)在ALI病例中对组织恶化的作用最大。在本研究中,我们基于先前鉴定的先导化合物设计并合成了一系列新的噻唑并[3,2-a]嘧啶衍生物,并评估了它们的抗炎活性。构效关系研究导致发现了两种高效抑制剂。发现这两种有前景的化合物在小鼠原代腹腔巨噬细胞(MPMs)中以剂量依赖性方式抑制脂多糖(LPS)诱导的IL-6和TNF-α释放。此外,给予这些化合物可改善肺组织病理学,并减轻体内LPS诱导的ALI。综上所述,这些数据表明这些新型噻唑并[3,2-a]嘧啶衍生物可开发为治疗ALI的候选药物。